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Abstract
Canine distemper virus (CDV), a close relative of measles virus (MV), is widespread and well known for its broad host range.
When the goal of measles eradication may be achieved, and when measles vaccination will be stopped, CDV might
eventually cross the species barrier to humans and emerge as a new human pathogen. In order to get an impression how
fast such alterations may occur, we characterized required adaptive mutations to the human entry receptors CD150 (SLAM)
and nectin-4 as first step to infect human target cells. Recombinant wild-type CDV-A75/17red adapted quickly to growth in
human H358 epithelial cells expressing human nectin-4. Sequencing of the viral attachment proteins (hemagglutinin, H, and
fusion protein, F) genes revealed that no adaptive alteration was required to utilize human nectin-4. In contrast, the virus
replicated only to low titres (102 pfu/ml) in Vero cells expressing human CD150 (Vero-hSLAM). After three passages using
these cells virus was adapted to human CD150 and replicated to high titres (105 pfu/ml). Sequence analyses revealed that
only one amino acid exchange in the H-protein at position 540 AspRGly (D540G) was required for functional adaptation to
human CD150. Structural modelling suggests that the adaptive mutation D540G in H reflects the sequence alteration from
canine to human CD150 at position 70 and 71 from Pro to Leu (P70L) and Gly to Glu (G71E), and compensates for the gain of
a negative charge in the human CD150 molecule. Using this model system our data indicate that only a minimal alteration,
in this case one adaptive mutation, is required for adaptation of CDV to the human entry receptors, and help to understand
the molecular basis why this adaptive mutation occurs.
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Introduction
The genus Morbilliviruses of the Paramyxoviridae family com-
prises the strictly human pathogen measles virus (MV), as well as
animal infectious agents such as rinderpest virus (RPV), canine
and phocine distemper viruses (CDV and PDV), peste des petits
ruminants virus (PPRV), and the cetacean dolphin and porpoise
Morbilliviruses (DMV and PMV). These viruses are all highly
contagious and cause systemic infections resulting in devastating
diseases in their respective hosts. Remarkably, all Morbilliviruses
except CDV have a tightly restricted host range, whereas CDV
has a broad host range infecting many carnivores including dogs,
wolves, hyena, foxes, raccoons and ferrets. In addition, CDV
strains substantially differ in virulence [1]. Expansions of the CDV
host range took place several times during the last decades. For
example, CDV from wolves, foxes, or dogs caused an epidemic
among seals in the Lake Baikal and the Caspian Sea, and also a
devastating disease within the lion population in the Serengeti
[2,3,4]. Moreover, infections of monkeys (Macaca fuscata and
Macaca mulata) with CDV resulting in quite high case fatality rates
have been observed [5,6,7,8]. During the recent outbreaks in
monkey breeding farms in China approximately 10,000 animals
were infected (25–60% disease incidence) and 5–30% of these died
[5].
These findings suggest that CDV may eventually infect humans
and spread in the human population. Indeed, specific anti-CDV
antibodies indicating a former CDV-infection have rarely been
detected in humans [9]. However, since antibodies generated in
dogs against the MV-vaccine provide effective cross-protection
against CDV [10], and since human sera containing anti-MV
antibodies cross-react with CDV, it is widely accepted that
measles-immunity protects humans at least partially from CDV
infections. In spite of these findings it should not be excluded that
CDV might eventually infect humans by escaping from the MV-
vaccine-induced immunity, or when vaccination might be stopped
after eradication of measles, which is now aspired by the World
Health Organization (WHO) to be achieved until 2020 [11].
Because of this potential threat for the human population it is
important to know how easy the species barrier to humans may be
crossed.
We here investigated the requirements of wild-type CDV
adaptation to the cognate human cellular MV receptors CD150
and nectin-4 [12,13,14,15,16,17]. We found that adaptation of
CDV to nectin-4 required none, and adaptation to CD150 only
one amino acid exchange in the viral H protein. This adaptation
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process swiftly occurred within only three virus passages. The
detected sequence alteration in the CDV-H protein reflects the
molecular changes between canine and human CD150.
Materials and Methods
Cell lines and viruses
The human caucasian brochioalveolar carcinoma cell line NCI-
H358 was obtained from Sigma-Aldrich (No. 95111733) and
grown in RPMI 1640 medium containing 10% fetal calf serum
(FCS). Vero cells expressing human CD150 (Vero-hSLAM) and
dog (canine) CD150 (Vero-cSLAM) were a gift of Dr. Y. Yanagi,
Fukuoka, Japan [18,19]. They were cultured in Eagle’s minimal
essential medium (EMEM) containing 5% FCS, 100 U/ml
penicillin and 100 mg/ml streptomycin. Recombinant wild-type
CDV-A75/17red [20,21,22] was propagated using Vero cells
expressing canine CD150 (Vero-cSLAM).
Virus preparation and titrations
Virus was harvested from 25 cm2 cell culture flasks by standard
freezing and thawing of infected cell monolayers (with 1 ml
medium/25 cm2 flask), scraping off the cells, homogenization, and
removal of cell debris by 15 min centrifugation at 4000 rpm.
Plaque assays were performed in triplicates in 6 well plates as
described earlier. Briefly, 70% confluent receptor-expressing Vero
cell monolayers were infected with a tenfold dilution series of the
virus in EMEM containing 0% FCS. Further incubation at 37uC
for 1–2 hour was followed by overlaying the wells with 3 ml of
double EMEM supplemented with 5% FCS and 2% Noble agar
(Sigma). Plaques were visualized after 6 days of incubation at 37u
by staining with neutral red.
Antibody infection inhibition assay
Vero-hSLAM cells were incubated with anti-human CD150
monoclonal antibody (mAb A12; BD Pharmingen) in 0% FCS
Medium for 3 h at room temperature. As isotype control purified
mouse IgG1k (clone MOPC-31C; BD Pharmingen) was used.
Antibody treated target cells were then infected with virus at a
MOI of 0.1 for 3 h before the medium was changed to FCS
containing medium and incubated further at 37uC. Fluorescence
and bright field pictures were taken at the respective time points.
RNA isolation, RT-PCR and sequencing
Total RNA from infected cells was prepared using Trizol
(Invitrogen) according to the manufacturer’s protocol. RT was
performed with random priming followed by PCR amplification of
CDV fragments using specific primers. PCR-fragments were
purified using QIA quick Gel Extraction Kit (QIAGEN) and
sequenced by dideoxynucleotide chain termination (ABI Prism)
using Big DyeH Cycle Sequencing Kit version 3.1. The primers
used for amplification and sequencing are available upon request.
CDV-H and –F expression plasmids and site directed
mutagenesis
Vero-cSLAM cells, in 6-well plates at 90% confluency, were co-
transfected with 2 mg of standard pCI-CDV-FA75/17 construct,
and 1 mg of pCI-CDV-HA75/17 plasmid or derivative mutant with
9 ml of Fugene HD (Roche), according to the manufacturer’s
protocol. Phase contrast pictures were taken 24 h post-transfection
by microscope (Olympus, Fluoroview, FV1000). The single
substitution D540G was introduced by changing the correspond-
ing GAC to GGC in pCI-CDV-HA757/17 using the quick-change
lightning site-directed mutagenesis kit (Stratagene) resulting in
plasmid pCI-CDV-HA75/17-D540G.
Structural modelling
Structural modelling was performed using the program Phyre2
and protein structure prediction on the web [23] and 3DLigand-
Site (Imperial College, London) [24].
Results
CDV attachment proteins can utilize human nectin-4
without adaptive alterations
For experimental adaptations described in this manuscript we
used CDV-A75/17red, a recombinant virulent wild-type CDV,
which was originally isolated from the brain of a CDV-infected
dog, cloned as a recombinant virus expressing tD tomato red
fluorescent protein from the 4th expression cassette, and propa-
gated using Vero-cSLAM cells [20,21,22]. In order to adapt
CDV-A75/17red to human nectin-4 we used the human epithelial
cell line H358 which is a target cell for measles virus expressing
nectin-4, but not CD150 [16,17]. The expression of nectin-4 and
absence of CD150 was confirmed by FACS analysis (not shown).
Human H358 cells were initially infected with CDV-A75/17red
at a MOI of 1.0 and incubated for the indicated times (Fig. 1 A).
At 8 days post-infection (dpi), when a considerable number of
individual infected cells were visible, virus was prepared and
titrated using Vero-cSLAM cells (1st passage of virus). H358 cells
were then infected with this virus at a MOI of 0.01 (Fig. 1 B). At
8 dpi virus was again prepared and titrated using Vero-cSLAM
cells (2nd passage). H358 cells were then infected with this virus at
a MOI of 0.01 (Fig. 1 C). Due to the advanced infection virus was
harvested already at 5 dpi (3rd passage) and titrated using Vero-
cSLAM cells. The viral titres that were determined for each
passage increased from 104 (1st passage) to 105.5 pfu/ml (3rd
passage), but did not further increase in following passages. This
3rd passage virus was then completely sequenced. We found
mutations outside of the H and F genes, but no sequence alteration
in the H and F genes in comparison to the parental recombinant
CDV-A75/17red indicating that no alteration of H is required for
adaptation to human nectin-4.
Adaptation of wild-type CDV-A75/17red to human CD150
(SLAM)
Human CD150-expressing Vero cells (Vero-hSLAM) were
initially infected with CDV-A75/17red at a MOI of 1.0 (Fig. 2
A). After 4 days, when large syncytia were visible, virus was
harvested (1st passage). Virus was titrated using Vero-cSLAM cells,
and Vero-hSLAM cells were infected at a MOI of 0.01 (Fig. 2 B).
After 4 dpi when large syncytia were observed virus was prepared
and again titrated using Vero-cSLAM cells (2nd passage). Vero-
hSLAM cells were then infected with this virus at a MOI of 0.01
(Fig. 2 C) and harvested at 3 dpi (3rd passage). The corresponding
titres of these virus passages as determined at day 4 (1st and 2nd
passage) or day 3 (3rd and 4th passage) using Vero-cSLAM cells are
given in (Fig. 2 D). Further passages of virus were produced
accordingly. In the first 3 passages viral titres increased to
approximately 105.5 pfu/ml. In later passages virus titres did not
further increase. This adaptation process was independently
repeated three times using original recombinant wild-type virus.
In all trials the swift adaptation within three passages was
reproduced. The adapted virus formed similar syncytia with
Vero-hSLAM cells as the parental virus with Vero-cSLAM cells
demonstrating that receptor interactions including fusion helper
functions appear to be fully adapted.
Swift Adaptation of CDV to Human Receptors
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e57488
To demonstrate that the adaptation occurred to human CD150,
and not to another receptor, we performed an infection inhibition
experiment using CD150-specific antibodies. Vero-hSLAM cells
were incubated with increasing concentrations of anti-CD150
antibody (mAb A12), or control antibody as indicated (Fig. 3) for
3 h prior to infection of cells with human CD150-adapted virus.
The infection was dose dependently inhibited with 1 and 5 mg/ml
CD150 antibody, but not with control antibody (isotype),
indicating that the virus indeed adapted to use human CD150
as receptor. As a further control Vero-cSLAM cells were pre-
incubated with mAb A12, which recognizes human CD150 but
not canine CD150 (not shown), and subsequently infected. As
expected, the antibody does not inhibit the infection of Vero-
cSLAM cells.
Next, single step growth curves of the viruses using various
target cells were determined (Fig. 4). Parental wild-type CDV-
A75/17red was originally grown using Vero-cSLAM cells. Its
growth was reduced by 2–3 logs when Vero-hSLAM cells were
infected (MOI= 0.01). In contrast, the growth curve of the human
CD150-adapted CDV-A75/17red using these cells (Vero-hSLAM)
was similar to the growth of parental CDV-A75/17red using Vero
cells expressing dog CD150 (Vero-cSLAM). These results indicate
that we obtained complete adaptation of CDV to the human
receptor. In addition we determined the growth of human CD150-
Figure 1. Infection of human epithelial cells H358 with CDV-A75/17red. H358 cells were infected with recombinant wild-type CDV-A75/17red
at a MOI of 1.0 (A), incubated for the indicated times and pictures of the red autofluorescence taken under UV light. At 8 days post-infection (dpi)
virus was prepared and titrated using Vero-cSLAM cells, and H358 cells infected with this virus at a MOI of 0.01 (B). After 8 dpi virus was again
prepared and titrated using Vero-cSLAM cells, and H358 cells were infected with this virus at a MOI of 0.01 for indicated times (C). Photomicrographs
of the autofluorescent virus-encoded tD tomato red were taken under UV light (bar = 100 mm).
doi:10.1371/journal.pone.0057488.g001
Figure 2. Infection of Vero-hSLAM cells with CDV-A75/17red. Human CD150-expressing Vero cells (Vero-hSLAM) were infected with
recombinant wild-type CDV-A75/17red at a MOI of 1.0 (A), incubated for the indicated times and pictures of the red autofluorescence taken under UV
light. At 4 days post-infection (dpi) virus was prepared and titrated, and Vero-hSLAM cells infected at a MOI of 0.01 (B). After 4 dpi virus was again
prepared and titrated, and Vero-hSLAM cells were infected with this virus at a MOI of 0.01 for indicated times (C). Titres of the virus preparations were
determined using Vero-cSLAM cells and are given in (D). Photomicrographs of the autofluorescent virus-encoded tD tomato red were taken under UV
light (bar = 100 mm).
doi:10.1371/journal.pone.0057488.g002
Swift Adaptation of CDV to Human Receptors
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adapted CDV-A75/17red on canine CD150 expressing cells.
Interestingly, the adaptation to human CD150 did not impair
growth of this virus on canine CD150 expressing cells.
Determination of sequence alterations of human CD150-
adapted CDV
As mentioned above, we repeated the adaptation to human
CD150 independently three times, and in all trials we observed the
same swift adaptation to the human receptor. To determine
sequence alterations required for this adaptation, sequences were
Figure 3. Infection with human CD150-adapted CDV-A75/17red is specifically inhibited by CD150 antibodies. Vero-hSLAM cells were
infected in the absence and presence of increasing concentrations of human CD150-specific monoclonal antibody A12 (A; 1 and 5 mg/ml), or isotype
control antibody (IgG1k; B; 1 and 5 mg/ml) for 2 days with human CD150-adapted CDV-A75/17red at a MOI of 0.1. As further control Vero cells
expressing canine CD150, which is not recognized by mAb A12, were infected in the absence and presence of mAb A12 (C; 1 and 5 mg/ml).
Photomicrographs of the autofluorescent virus-encoded tD tomato red were taken under UV light (bar = 100 mm).
doi:10.1371/journal.pone.0057488.g003
Figure 4. Comparison of single step growth curves of parental and adapted CDV-A75/17red using canine and human CD150-
expressing target cells. Vero-cSLAM cells (open circles) and Vero-hSLAM cells (closed circles) were infected with parental CDV-A75/17red, and Vero-
cSLAM cells (blue triangles) and Vero-hSLAM cells (red squares) were infected with human CD150-adapted CDV-A75/17red (CDV-A75-ad) at a MOI of
0.01 and incubated for indicated times before harvesting cell bound plus released virus. The viruses were then titrated using the optimal target cells
for each virus (n = 3, using 3 independently adapted viruses).
doi:10.1371/journal.pone.0057488.g004
Swift Adaptation of CDV to Human Receptors
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determined from the original parental recombinant virus and 10
virus clones obtained by plaque picking from the independently
adapted viruses. In all sequenced clones of adapted viruses we
reproducibly found the same sequence alteration A to G at
nucleotide position 8697 in the genome of CDV-A75/17
(AF164967) changing GAC to GGC leading to one expressed
amino acid difference in the CDV-H protein at position 540
AspRGly (D540G). Amino acid 540 is located within the CD150
binding region of the H protein spanning approximately amino
acid 500 to 550 of the CDV-H protein [25]. Aligned sequences of
the receptor binding regions of H proteins of CDV-A75/17red,
human CD150-adapted CDV, other CDV strains, and various
Morbilliviruses are shown in Fig. 5.
Recombinant D540G mutation confers improved
interaction with human CD150
In order to prove the functional consequences of the detected
D540G mutation, we introduced it into an expression vector for
CDV-H for transfection experiments. A glycine (G) at position 540
was generated by site directed mutagenesis in the expression
plasmid for CDV-HA75/17 resulting in pCI-CDV-HA75/17-D540G.
Vero-cSLAM and Vero-hSLAM cells were transfected with
plasmids expressing wild-type HA75/17 and F, or expressing the
mutated HA75/17-D540G and F. In Vero-cSLAM cells large syncytia
were observed at 24 h after transfection with both combinations of
plasmids (Fig. 6). In contrast, in Vero-hSLAM cells syncytia were
observed only after transfection with plasmids encoding HA75/17-
D540G and F, but not after transfection with plasmids encoding for
wild-type H and F. This demonstrates that the D540G mutation in
CDV-HA75/17 is necessary and sufficient to mediate a functional
interaction with human CD150 providing full membrane fusion
capacity of the viral H and F envelope glycoprotein complex.
Modelling of the haemagglutinin-CD150 interaction
Modelling of CDV-HD540G and hCD150 revealed that amino
acid 540 in CDV-H is located opposite to a loop in the V-like
domain 1 of human CD150 formed by amino acids 70 and 71,
Leu and Glu (L and E), respectively (Fig. 7). Interestingly, these
two residues differ in canine and human CD150 (Fig. 8). This
difference probably exerts the adaptive constraint for amino acid
540 in the interacting CDV-H protein that leads to the observed
mutation. The residue at position 71 is a non-charged G in canine
CD150, but a charged E in human CD150. It is likely that this
charge alteration provoked the adaptive mutation D540G, from a
charged to a non-charged residue in the CDV-H protein. Thus,
D540G is likely to compensate for the amino acid alteration in the
receptor and provides a balanced charge distribution in the CDV-
H-receptor complex. Further structural analyses will be undertak-
en to investigate the molecular interactions leading to this
observed adaptive mutation.
Discussion
Cellular receptors play an important role by controlling the first
steps of infection, and, if they are sufficiently different in various
hosts, they can provide effective species barriers. Corroborating
their similarity in cell tropism and pathogenicity, various
Morbilliviruses such as MV, CDV and RPV use the species
orthologues of CD150 and nectin-4 as major uptake receptors
[16,17,26,27,28,29,30]. Our infection experiment of H358 cells
with CDV-A75/17red revealed that few passages were required for
Figure 5. Comparison of the CD150 binding sites of Morbillivirus H proteins. The receptor (CD150) binding site of the Morbillivirus H-
proteins comprises approximately amino acid 500 to 550. CDV-H position 540 (corresponding to MV-H position 544) is located nearby the cognate
receptor interacting residues 525, 526, and 529 [25]. CDV-A75-ad=human CD150-adapted CDV-A75/17red.
doi:10.1371/journal.pone.0057488.g005
Figure 6. Syncytium formation after co-transfection of plas-
mids expressing CDV-H and -F proteins. Vero-cSLAM and Vero-
hSLAM cells were transfected with plasmids expressing wild-type CDV-
HA75/17 and mutated HA75/17-D540G in combination with wild-type CDV-F
as indicated, and incubated for 24 h before phase-contrast micropho-
tographs were taken (bar = 100 mm).
doi:10.1371/journal.pone.0057488.g006
Swift Adaptation of CDV to Human Receptors
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adaptation of this virus to human target cells, while the location of
the detected mutations outside of H and F clearly indicated that
there is no need for adaptation of H to human nectin-4. It is likely
that the mutations outside of H and F are required for intracellular
adaptation to human host factors, which, however, was not subject
of this study and requires further investigations. Nectin-4 is highly
conserved between species with almost identical extracellular
domains of canine and human nectin-4. Consequently, as
observed by us and others [31], no adaptive mutation is required
for wild-type CDV to use human nectin-4 as receptor.
With 64% identity, canine and human CD150 are somewhat
less conserved. This difference is reflected by our findings that an
adaptation phase is required, and that one amino acid exchange at
position 540 improves binding to the human receptor. It is
astonishing how quickly the adaptation occurred (3 passages),
although we started from a cloned recombinant virus with a
defined sequence, which was confirmed by sequencing. This
parental virus was propagated exclusively using Vero-cSLAM cells
before. Given the swift adaptation, it is likely that in a sufficiently
large pool of parental virus, as used for initial infection of Vero-
hSLAM cells at a MOI of 1.0, the mutation emerges spontane-
ously. Three passages of ‘‘adaptation’’ are then sufficient to select
for the functional H protein. Tatsuo and co-workers investigated
earlier the usage of species-specific CD150 as cellular receptors for
Morbilliviruses [15]. They analyzed two CDV strains that were
isolated using marmoset B95a cells and found that these viruses
equally well were taken up by and formed syncytia on CHO cells
expressing human or canine CD150. In the light of our results, it is
likely that these two CDV strains adapted already during their
isolation procedure to marmoset CD150, which is almost identical
with human CD150, and therefore can utilize human CD150 very
efficiently.
Our selection procedure reproducibly led to viruses bearing the
same D540G mutation in the H gene and provided viruses fully
adapted to the human receptor. That the observed adaptive
mutation is required for a balanced charge distribution as
consequence of the alteration in the human CD150 at position
71 appears to be conclusive. This interpretation is supported by
the structural modelling data. Our modelling is based on structural
analysis of wild-type MV-H interaction with CD150, which
revealed the prerequisites for a functional interaction [32]. As
shown in Fig. 6, the D540G mutation confers good fusion capacity
to the receptor interacting viral envelope proteins, which,
however, is not completely as good as observed for the interaction
of parental CDV with canine CD150. In spite of this slight
difference in the cell-cell fusion, we did not observe a remarkable
difference between the titres of these viruses in the single step
growth curves. The titre of the adapted virus on Vero-hSLAM
cells is even slightly higher at day 3 to 5 (Fig. 4). When syncytia
become very large very quickly, membrane parts in the middle
Figure 7. Structural model of the CDV-H-CD150 interaction. Side (A) and top (B) view of the globular head of CDV-H (amino acids 188 to 602)
presented in magenta with highlighted amino acid 540 G (green), and of the interacting first V-like domain of human CD150 (amino acids 32 to 140)
shown in blue with highlighted amino acid 71 E (yellow). The structures were modelled based on the crystal structure of MV-H bound to CD150 [33].
doi:10.1371/journal.pone.0057488.g007
Figure 8. Comparison of the canine and human CD150 sequences around the Morbillivirus H binding site. The MV-H binding site of
CD150 was mapped between amino acid 61 and 131 [33]. Amino acid 71 is an uncharged G in dog CD150, and a negatively charged E in human
CD150 (NM_001003084 [25]).
doi:10.1371/journal.pone.0057488.g008
Swift Adaptation of CDV to Human Receptors
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may detach, and the amount of newly synthesized virus decreases.
Therefore, a slightly reduced fusogenicity and subsequent less
detachment from the plastic dish may support a slight increase in
virus titre. It was also interesting to observe that the adaptation of
CDV-A75/17red to human CD150 did not impair its growth
capacity on Vero-cSLAM cells. Although improving the interac-
tion with human CD150, the D540G mutation obviously does not
affect the interaction of H with canine CD150. Further structural
analyses may clarify this point.
Following the outbreaks of CDV infections in animal facilities in
China [5,7], a CDV outbreak occurred in cynomolgus monkeys
(Macaca fascicularis) in Japan 2008 [6]. A corresponding CDV strain
was isolated (CYN07-dV) and characterized, which efficiently
utilized macaca CD150 as entry receptor [6]. Since the amino acid
sequence of Macaca mulatta CD150 including position 70/71 is
practically identical to the human sequence, one may suppose that
the human CD150-positive cells should be well infected. In spite of
this, the isolated virus did not very well infect Vero-hSLAM cells
[6]. The amino acid exchange D540G as observed by us for CDV-
A75/17-adaptation was not found in CYN07-dV [6]. Subtle
differences between human and macaca CD150 might play a role,
such as position 28 (R and H, respectively) and 49 (Y and H,
respectively) and contribute to the observed effects.
Taken together, there is obviously no high hurdle for CDV to
adapt and utilize human entry receptors. However, in spite of this
swift adaptation, these data should not lead to the misunderstand-
ing that other human target cells or humans will be infected so
easily. It is clear that adaptation to human entry receptors is only
the first step to full adaptation to human target cells, and that
alterations in other viral genes are required for intracellular
adaptation.
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